Tissue Factor-Factor VIIa complex (TF-FVIIa)

The Tissue Factor-Factor VIIa (TF-FVIIa) complex is the primary physiological initiator of the blood coagulation cascade [UniProt P13726]. It is formed upon vascular injury when the integral membrane protein Tissue Factor (TF) is exposed to and binds circulating activated Factor VII (FVIIa) [PubMed: 12166486]. This bimolecular complex functions as a serine protease, specifically activating Factor IX and Factor X to generate thrombin, which ultimately leads to fibrin clot formation [PubMed: 15507107]. In addition to its central role in hemostasis, the TF-FVIIa complex acts as a signaling scaffold that activates Protease-Activated Receptor 2 (PAR-2), influencing processes such as inflammation, angiogenesis, and tumor metastasis [PubMed: 22403334]. Pathological expression of TF is associated with various conditions, including deep vein thrombosis, myocardial infarction, and the hypercoagulable state in cancer [PubMed: 12166486]. Consequently, the TF-FVIIa complex is a significant therapeutic target for the development of anticoagulants and anti-tumor agents, with various inhibitors such as monoclonal antibodies and small molecules being explored to modulate its activity [PubMed: 15507107].

Other names

Coagulation factor III-activated factor VII complexThromboplastin-Factor VIIa complexCD142-FVIIa complexExtrinsic tenase complex

Inhibition of the proteolytic activity of the TF-FVIIa complex to prevent the activation of Factor X and Factor IX, thereby suppressing thrombin generation and fibrin formation [PubMed: 15507107]. It also involves blocking TF-mediated intracellular signaling through protease-activated receptors (PARs) [PubMed: 22403334].